Roche, Discuva in antibiotics deal

Roche (SIX:ROG; OTCQX:RHHBY) and Discuva Ltd. (Cambridge, U.K.) partnered to discover and develop antibiotics to treat multi-drug resistant (MDR) Gram-negative bacteria using Discuva's selective antibiotic target identification (SATIN) technology. Discuva will receive $16 million up front and is eligible for research fees and up to $175 million in milestones per product, plus royalties. Roche said the partners will jointly conduct lead identification and optimization. The pharma will be responsible for preclinical and clinical development. ...